Neurogene Inc. SEC filings NGNE
Neurogene Inc. has 750 filings in SEC EDGAR's recent list, going back to Jun 25, 2007. Its latest annual report, Form ARS, was filed on Apr 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 11, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B5 | Prospectus supplement | Jul 2, 2026 | — |
| 424B5 | Prospectus supplement | Jun 30, 2026 | — |
| S-8 | Employee stock plan registration | Mar 24, 2026 | — |
| 424B5 | Prospectus supplement | Aug 11, 2025 | — |
| 424B3 | Prospectus | Apr 1, 2025 | — |
| S-3 | Shelf registration | Mar 24, 2025 | — |
| POS AM | Filing | Mar 24, 2025 | — |
| S-8 | Employee stock plan registration | Mar 24, 2025 | — |
| 424B3 | Prospectus | Dec 18, 2024 | — |
| S-1 | Registration statement | Dec 2, 2024 | — |
| S-8 | Employee stock plan registration | Feb 20, 2024 | — |
| S-4/A | Filing | Nov 8, 2023 | — |
| S-4/A | Filing | Oct 18, 2023 | — |
| S-4/A | Filing | Sep 28, 2023 | — |
| S-4 | Registration for a merger or exchange | Aug 21, 2023 | — |
| S-8 | Employee stock plan registration | Mar 21, 2023 | — |
| S-3 | Shelf registration | May 9, 2022 | — |
| S-8 | Employee stock plan registration | Mar 1, 2022 | — |
| 424B5 | Prospectus supplement | Nov 4, 2021 | — |
| S-8 | Employee stock plan registration | Mar 25, 2021 | — |
| S-3 | Shelf registration | Dec 11, 2020 | — |
| 424B5 | Prospectus supplement | Jul 2, 2020 | — |
| 424B5 | Prospectus supplement | Jul 1, 2020 | — |
| S-8 | Employee stock plan registration | May 6, 2020 | — |
| S-8 | Employee stock plan registration | Mar 12, 2020 | — |
| 424B5 | Prospectus supplement | Dec 18, 2019 | — |
| 424B5 | Prospectus supplement | Dec 17, 2019 | — |
| S-8 | Employee stock plan registration | Nov 15, 2019 | — |
| S-8 | Employee stock plan registration | Mar 12, 2018 | — |
| S-3 | Shelf registration | Mar 12, 2018 | — |
| S-8 | Employee stock plan registration | Mar 9, 2017 | — |
| 424B3 | Prospectus | Jan 20, 2017 | — |
| S-3 | Shelf registration | Jan 6, 2017 | — |
| 424B5 | Prospectus supplement | Sep 20, 2016 | — |
| 424B5 | Prospectus supplement | Sep 19, 2016 | — |
| S-8 | Employee stock plan registration | Mar 14, 2016 | — |
| S-3 | Shelf registration | Dec 21, 2015 | — |
| 424B5 | Prospectus supplement | Sep 10, 2015 | — |
| 424B5 | Prospectus supplement | Sep 8, 2015 | — |
| 424B5 | Prospectus supplement | Apr 9, 2015 | — |
| S-3 | Shelf registration | Apr 1, 2015 | — |
| S-8 | Employee stock plan registration | Apr 1, 2015 | — |
| S-8 | Employee stock plan registration | Mar 11, 2014 | — |
| 424B4 | Prospectus | Mar 7, 2014 | — |
| S-1/A | Amended registration statement | Feb 28, 2014 | — |
| S-1 | Registration statement | Jan 28, 2014 | — |
Showing 46 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NGNE (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1404644
- Former names
- Neoleukin Therapeutics, Inc. (until Dec 6, 2023); AQUINOX PHARMACEUTICALS, INC (until Aug 12, 2019); AQUINOX PHARMACEUTICALS (USA) INC (until Dec 24, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.